Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000819 · ClinicalTrials.gov registry record · Phase 2
A Phase II Randomized, Double-Blind, Placebo-Controlled Trial to Determine the Efficacy of Prednisone Therapy in HIV-Associated Nephropathy (HIVAN)
A Phase 2 study of HIV Infections and AIDS-Associated Nephropathy, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 54
- Enrollment target
- 8
- Study locations
NCT00000819 is a Phase 2 study of HIV Infections and AIDS-Associated Nephropathy that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 54 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (88% lower). The trial reports 8 study locations across 5 states.
The verdict
NCT00000819, a Phase 2 study of HIV Infections and AIDS-Associated Nephropathy, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 54 participants
- Enrollment target
- 8
- Study locations
Study Summary
To determine the efficacy and safety of prednisone in patients with HIV-associated nephropathy. To determine the effects of prednisone on serum creatinine, urinary protein, and creatinine clearance. HIV-associated nephropathy is characterized by heavy proteinuria, rapidly progressive renal insufficiency, and distinct nephropathologic changes. The syndrome most often occurs in patients with advanced HIV disease. Little is known about the effects of corticosteroids on the progression of HIV disease. In light of the possible beneficial effects of corticosteroids on HIV-associated nephropathy, a controlled trial using prednisone is warranted.
Conditions Studied
Interventions
- DRUG Prednisone
Study Locations (8)
California
- UCLA CARE Center CRS - Los Angeles
- Ucsf Aids Crs - San Francisco
- Harbor-UCLA Med. Ctr. CRS - Torrance
Ohio
- Case CRS - Cleveland
- MetroHealth CRS - Cleveland
Indiana
- Indiana Univ. School of Medicine, Infectious Disease Research Clinic - Indianapolis
Maryland
- Johns Hopkins Adult AIDS CRS - Baltimore
New York
- Beth Israel Med. Ctr. (Mt. Sinai) - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Est. Completion | 1996-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00000819
The ClinicalTrials.gov registry entry for NCT00000819 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (88% lower). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which Prednisone is the first listed.
NCT00000819 reports 8 study locations spanning 5 distinct geographic areas - top geographies include California, Ohio, Indiana.
Frequently Asked Questions
What is clinical trial NCT00000819 about?
NCT00000819 is a clinical study titled "A Phase II Randomized, Double-Blind, Placebo-Controlled Trial to Determine the Efficacy of Prednisone Therapy in HIV-Associated Nephropathy (HIVAN)". To determine the efficacy and safety of prednisone in patients with HIV-associated nephropathy. To determine the effects of prednisone on serum creatinine, urinary protein, and creatinine clearance. HIV-associated nephropathy is characterized by heavy proteinuria, rapidly progressive renal insuffic...
What is the current status of trial NCT00000819?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 54 participants. Estimated completion is 1996-09.
What conditions does trial NCT00000819 study?
This clinical trial studies the following conditions: HIV Infections, AIDS-Associated Nephropathy.
What interventions are being tested in trial NCT00000819?
The interventions under investigation include: Prednisone (DRUG).
Who is sponsoring clinical trial NCT00000819?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00000819 being conducted?
This trial has 8 study locations across California, Indiana, Maryland, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)
RECRUITING · Phase 2
-
Microbiome Metabolites and Alcohol in HIV to Reduce CVD RCT
RECRUITING · Phase 2
-
Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)
RECRUITING · Phase 2
-
Imaging Immune Activation in HIV by PET-MR
RECRUITING · Phase 2
-
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.